Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

This study is testing a new drug called VT3989 in patients with certain advanced cancers — specifically mesothelioma (a cancer often linked to asbestos exposure) and a type of lung cancer (NSCLC) with specific gene mutations. Researchers are exploring VT3989 on its own and in combination with other treatments. **You may be eligible if you:** - Have been diagnosed with malignant mesothelioma that has spread and have not yet received systemic (whole-body) cancer treatment, OR - Have advanced lung cancer (NSCLC) with specific mutations (exon 19 deletion or exon 21 L858R), with or without prior treatment with a drug called osimertinib - Have measurable disease on scans - Are in good enough health to participate (ECOG performance status 0–1) - Have adequate liver, kidney, and blood function **You may NOT be eligible if you:** - Have active brain metastases (cancer that has spread to the brain) or a primary brain tumor - Have had cancer spread to the lining around the brain or spinal cord Talk to your doctor to see if this trial is right for you.